Chiappini, Elena http://orcid.org/0000-0002-1476-4752
Santamaria, Francesca
Marseglia, Gian Luigi
Marchisio, Paola
Galli, Luisa
Cutrera, Renato
de Martino, Maurizio
Antonini, Sara
Becherucci, Paolo
Biasci, Paolo
Bortone, Barbara
Bottero, Sergio
Caldarelli, Valeria
Cardinale, Fabio
Gattinara, Guido Castelli
Ciarcià, Martina
Ciofi, Daniele
D’Elios, Sofia
Di Mauro, Giuseppe
Doria, Mattia
Indinnimeo, Luciana
Lo Vecchio, Andrea
Macrì, Francesco
Mattina, Roberto
Miniello, Vito Leonardo
del Giudice, Michele Miraglia
Morbin, Guido
Motisi, Marco Antonio
Novelli, Andrea
Palamara, Anna Teresa
Panatta, Maria Laura
Pasinato, Angela
Peroni, Diego
Perruccio, Katia
Piacentini, Giorgio
Pifferi, Massimo
Pignataro, Lorenzo
Sitzia, Emanuela
Tersigni, Chiara
Torretta, Sara
Trambusti, Irene
Trippella, Giulia
Valentini, Diletta
Valentini, Sandro
Varricchio, Attilio
Verga, Maria Carmen
Vicini, Claudio
Zecca, Marco
Villani, Alberto
Funding for this research was provided by:
Valeas Inc, Milan, Italy
Article History
Received: 1 March 2021
Accepted: 9 September 2021
First Online: 25 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: The competing interests of the panel members are reported as following:-EC: Valeas Spa Italia.-RC: Abbvie, Aboca, Chiesi, Glaxosmitkline, Omron, Ailiquide.-PM: Valeas Spa Italia, OM Pharma S.A. e DMG.-RM: Grunenthal.-FS: Chiesi; AbbVie; Valeas.The other authors declare that they have no competing interests.